Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Increased by Bank of Montreal Can

Bank of Montreal Can raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating) by 4.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 77,081 shares of the biopharmaceutical company’s stock after buying an additional 3,330 shares during the period. Bank of Montreal Can owned about 0.06% of Alnylam Pharmaceuticals worth $11,218,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Alnylam Pharmaceuticals by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock worth $1,768,291,000 after purchasing an additional 126,373 shares during the period. Wellington Management Group LLP boosted its stake in Alnylam Pharmaceuticals by 2.8% in the 1st quarter. Wellington Management Group LLP now owns 7,034,487 shares of the biopharmaceutical company’s stock worth $1,148,660,000 after purchasing an additional 190,057 shares during the period. Capital World Investors boosted its stake in Alnylam Pharmaceuticals by 1,781.1% in the 1st quarter. Capital World Investors now owns 5,999,674 shares of the biopharmaceutical company’s stock worth $979,687,000 after purchasing an additional 5,680,728 shares during the period. State Street Corp boosted its stake in shares of Alnylam Pharmaceuticals by 2.1% during the 1st quarter. State Street Corp now owns 2,909,490 shares of the biopharmaceutical company’s stock valued at $475,091,000 after buying an additional 59,101 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Alnylam Pharmaceuticals by 17.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,997,762 shares of the biopharmaceutical company’s stock valued at $326,975,000 after buying an additional 295,092 shares during the period. 93.21% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $208.49 on Thursday. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.48 and a quick ratio of 3.33. The firm has a market capitalization of $25.65 billion, a price-to-earnings ratio of -21.34 and a beta of 0.54. The company’s fifty day moving average is $203.32 and its two-hundred day moving average is $177.71. Alnylam Pharmaceuticals, Inc. has a 52-week low of $117.58 and a 52-week high of $236.80.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last issued its earnings results on Thursday, October 27th. The biopharmaceutical company reported ($3.32) earnings per share for the quarter, missing the consensus estimate of ($1.77) by ($1.55). Alnylam Pharmaceuticals had a negative net margin of 123.02% and a negative return on equity of 430.74%. The business had revenue of $264.31 million for the quarter, compared to analyst estimates of $291.81 million. During the same quarter last year, the firm posted ($1.72) earnings per share. Alnylam Pharmaceuticals’s revenue was up 40.9% on a year-over-year basis. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -9.41 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group lifted their target price on shares of Alnylam Pharmaceuticals from $218.00 to $232.00 and gave the company a “buy” rating in a research note on Monday, October 3rd. Royal Bank of Canada lifted their target price on shares of Alnylam Pharmaceuticals from $225.00 to $250.00 and gave the company an “outperform” rating in a research note on Tuesday, September 20th. Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $220.00 to $210.00 and set an “equal weight” rating for the company in a research note on Friday, October 28th. Evercore ISI raised their price target on shares of Alnylam Pharmaceuticals to $252.00 in a report on Tuesday, August 9th. Finally, The Goldman Sachs Group raised their price target on shares of Alnylam Pharmaceuticals from $239.00 to $270.00 and gave the company a “buy” rating in a report on Friday, October 28th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $232.37.

Alnylam Pharmaceuticals Company Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Read More

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.